New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
06:41 EDTAKRXAkorn long-term fundamentals remain unchanged, says Leerink
Leerink says Akron's long-term fundamentals remain unchanged following the company's FY13 guidance call. The firm thinks management met expectations on the top line, provided a reasonable explanation on margins and slightly disappointed on manufacturing capacity expansion. Leerink raised its price target for Akorn shares to $16 from $14-$15 and keeps an Outperform rating on the name.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
16:27 EDTAKRXOn The Fly: Top stock stories for Monday
Stocks on Wall Street began the session in positive territory and saw the Nasdaq and S&P 500 briefly hit new all-time highs in the process. By lunch time the Nasdaq and S&P crossed into negative ground while the Dow continued to struggle. The market limped into the close, digesting some of its recent gains, as investors prepared for the next round of earnings reports due out after the close, to be headlined by Apple (AAPL). ECONOMIC EVENTS: In the U.S., Markit's flash services PMI fell 1.4 points to 57.8 in April, versus the consensus forecast for a 59.5 reading. The Dallas Fed's manufacturing index remained weak at -16.0 in April, versus the consensus forecast for a -12.0 reading. In Europe, Spanish Prime Minister Mariano Rajoy lifted his nation's GDP forecast to 2.9% from 2.4% for 2015. COMPANY NEWS: Shares of Deutsche Bank (DB) trading in New York dropped $1.65, or 4.82%, to $32.61 after the bank, along with publishing its quarterly results, unveiled a major strategic overhaul. The bank plans to cut annual costs by another EUR3.5B, reduce the size of its securities business and lower its Postbank holdings next year to sub-50% from 94% by selling shares on the market before reducing its stake to zero in the medium term... Applied Materials (AMAT) and Tokyo Electron announced that they have agreed to terminate their merger agreement after the U.S. Department of Justice advised the parties that the coordinated remedy proposal submitted to all regulators would not be sufficient to replace the competition lost from the merger, leading the companies to determined that there is "no realistic prospect for the completion of the merger." Applied Materials also announced that its board has approved a new share repurchase program authorizing up to $3B in repurchases over the next three years beginning in Q3, but its shares fell $1.83, or 8.42%, to $19.97 following the news. MAJOR MOVERS: Among the notable gainers was iGATE (IGTE), which rose $1.54, or 3.36%, to $47.39 after the company entered into a definitive merger agreement under which Capgemini will acquire IGATE for a cash consideration of $48 per share in a transaction will amount to $4B. Also higher was Tesla Motors (TSLA), which gained $13.04, or 5.97%, to $231.47 after Deutsche Bank analyst Rod Lache wrote in a note to investors that the company's soon to be unveiled electricity storage products may boost the company's results more than the Street expects. Among the noteworthy losers was Celladon (CLDN), which plunged $11.04, or 80.7%, to $2.64 and was downgraded by Street research firms after reporting that its phase 2b trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent Mydicar did not meet its primary and secondary endpoints. Also lower were shares of Akorn (AKRX), which fell $12.27, or 22.21%, to $42.97 after the drugmaker announced late Friday that it will need to further restate its previously issued financial statements for 2014. INDEXES: The Dow fell 42.17, or 0.23%, to 18,037.97, the Nasdaq slid 31.84, or 0.63%, to 5,060.25, and the S&P 500 dropped 8.77, or 0.41%, to 2,108.92.
12:28 EDTAKRXOptions with increasing implied volatility
Options with increasing implied volatility: THRX ARRY AKRX DECK HSBC
12:25 EDTAKRXOn The Fly: Top stock stories at midday
Subscribe for More Information
12:20 EDTAKRXAnother restatement sinks shares of generic drugmaker Akorn
Subscribe for More Information
10:03 EDTAKRXAkorn drops sharply on financial restatements news
The stock is down over 20% at time of writing to $43.93. At that price next support is at $43.22 and then at $41.34. Resistance is at $44.48.
10:00 EDTAKRXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 3D Systems (DDD) downgraded to Hold from Buy at Canaccord... Akorn (AKRX) downgraded to Neutral from Overweight at Piper Jaffray... Allegiant Travel (ALGT) downgraded to Fair Value from Buy at CRT Capital... Altera (ALTR) downgraded to Neutral from Outperform at Baird... Amazon.com (AMZN) downgraded on valuation at Argus... American Science & Engineering (ASEI) downgraded to Sell from Fair Value at CRT Capital... Basic Energy (BAS) downgraded to Underperform from Neutral at Macquarie... C.H. Robinson (CHRW) downgraded to Sell from Neutral at UBS... Celladon (CLDN) downgraded to Neutral from Buy at Roth Capital... DST Systems (DST) downgraded to Neutral from Outperform at Credit Suisse... DeVry (DV) downgraded on weaker than expected outlook at Stifel... Eaton Vance (EV) downgraded to Sell from Neutral at Citigroup... Emerge Energy (EMES) downgraded to Hold from Buy at Wunderlich... FMC Technologies (FTI) downgraded to Accumulate from Speculative Buy at Global Hunter... Fibria Celulose (FBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Forum Energy (FET) downgraded to Neutral at Baird... Gulf Island Fabrication (GIFI) downgraded to Hold from Accumulate at Johnson Rice... Hancock Holding (HBHC) downgraded to Hold from Buy at Drexel Hamilton... Hi-Crush Partners (HCLP) downgraded to Hold from Buy at Wunderlich... Houghton Mifflin (HMHC) downgraded to Neutral from Buy at Citigroup (Friday)... Infosys (INFY) downgraded to Hold from Buy at Deutsche Bank... Marvell (MRVL) downgraded to Hold from Buy at Craig-Hallum... Merge Healthcare (MRGE) downgraded to Hold from Buy at Topeka... Oceaneering (OII) downgraded to Neutral from Buy at Goldman... Omega Healthcare (OHI) downgraded at BofA/Merrill... Perrigo (PRGO) downgraded to Neutral from Buy at UBS... Petrobras (PBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Procter & Gamble (PG) downgraded on lack of upside at CLSA... ResMed (RMD) downgraded to Neutral from Buy at Goldman... Seadrill (SDRL) downgraded to Sell from Neutral at Citigroup... Six Flags (SIX) downgraded to Neutral from Buy at Goldman... Stratasys (SSYS) downgraded to Hold at Canaccord... Telecom Italia (TI) downgraded to Neutral from Buy at BofA/Merrill... Twitter (TWTR) downgraded to Neutral from Buy at SunTrust... United Continental (UAL) downgraded to Fair Value from Buy at CRT Capital... Virgin America (VA) downgraded to Sell from Buy at CRT Capital.
09:22 EDTAKRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:51 EDTAKRXJefferies wonders if Akorn errors discovered by potential acquirer
Subscribe for More Information
07:14 EDTAKRXAkorn base business still well positioned, says JPMorgan
Subscribe for More Information
06:44 EDTAKRXAkorn downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
April 24, 2015
16:39 EDTAKRXAkorn down 10% after announcing additional financial restatements needed
Subscribe for More Information
16:16 EDTAKRXAkorn to resume trading at 4:35 pm ET
Subscribe for More Information
16:08 EDTAKRXAkorn backs FY15 adjusted EPS view $1.88-$1.98, consensus $1.95
16:07 EDTAKRXAkorn to make additional financial restatements
Subscribe for More Information
April 21, 2015
11:57 EDTAKRXAkorn rises, Perrigo slips after Teva makes long-rumored Mylan bid
The shares of drugmaker Akorn (AKRX) are rising after Israeli pharmaceutical company Teva (TEVA) earlier today made a takeover bid for another company in the space, generic drugmaker Mylan (MYL). WHAT'S NEW: Teva announced an $82 per share takeover bid for generic drug maker Mylan earlier today. The latter company said that Teva's takeover offer is a more attractive option for it than acquiring another generic drug maker, Perrigo (PRGO). On April 8, Mylan made a $205 per share takeover offer for Perrigo. Teva's bid comes less than a week after Mylan Chairman Robert Coury said that rumors of potential interest from Teva had been "circulating for some time," but that such a combination was "without sound industrial logic or cultural fit" and would be unlikely to receive antitrust regulatory clearances. ANALYST OPINION: In a note to investors on April 15, RBC Capital analyst Randall Stanicky wrote that Perrigo may have been engaging other companies in talks after Mylan came public with its takeover offer. Stanicky said he saw no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. The analyst added that Acorn is well-positioned as a derivative takeover target following Mylan's offer for Perrigo, noting Acorn's strong growth and high tax rate. In a note to investors yesterday, Citigroup said it believed a potential takeover of Mylan by Teva would have to be friendly after its legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. Citi estimated an $80 per share bid for Mylan would be 25%-35% accretive from 2016 onward for Teva while a $90 per share bid would be 20%-30% accretive. The firm added that it believes it is likely that Mylan received resistance from shareholders since the announcement of its proposed acquisition of Perrigo. PRICE ACTION: In late morning trading, Akorn rose 2.2% to $55.85, Perrigo dropped 2.4% to $193.24, Mylan jumped 9.3% to $74.39, and Teva rose 2.1% to $64.64.
April 15, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTAKRXRBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
08:19 EDTAKRXAkorn management to meet with Deutsche Bank
Subscribe for More Information
06:24 EDTAKRXAkorn initiated with an Overweight, $61 target at JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use